ASN insights on felzartamab, a CD38-targeted therapy, show sustained immune modulation in IgA nephropathy, offering a novel treatment approach.
Jürgen Floege, MD
Advertisement
Jürgen Floege, MD, senior professor at RWTH Aachen University’s Medical School
Articles by Jürgen Floege, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
SimpleScreen CRC Blood Test Meets Endpoints in Clinical Validation Study
2
Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
3
Eplontersen Misses Primary Endpoint in Phase 3 ATTR-CM Trial
4
Biologic Therapy for Asthma and COPD: Real-World Perspectives From APPs
5